The Cardiology Advisor

Strategies to Optimize Nonpharmacologic Interventions in Heart Failure

Nonpharmacologic heart failure management and interventions can reduce cardiovascular risk factors and carotid intima-media ...
The Cardiology Advisor

AHA Statement on Standardizing Hemodynamic Protocols for HF and PH

AHA scientific statement provides a framework for standardizing baseline and provocative invasive hemodynamic protocols in HF ...
Open Heart

Advanced Cardiogenic-shock Team versus standard care in cardiogenic SHOCK: a single centre service evaluation project

Background Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) carries high mortality. Early ...
Medscape

Don’t Overlook Heart Failure as the First Major CV Event in T2D

Cardiovascular disease that presents first as heart failure is common in type 2 diabetes and its risk factors differ from those of cardiovascular disease that present first as atherosclerotic events.

Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

Takeda (TSE:4502/NYSE:TAK) today announced the U.S. availability of GAMMAGARD LIQUID™ ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, by prescription, ...